Cyclin-Dependent Kinase 9 (CDK9) Inhibitor – Pipeline Review, 2019

Cyclin-Dependent Kinase 9 (CDK9) inhibitor belongs to the family of cyclin-dependent protein kinase (CDK). The members of this family possess high similarity with the gene products of Schizosaccharomyces pombe cdc2 and Saccharomyces cerevisiae cdc28. Cyclin-dependent protein kinase is primarily responsible for regulating important cell cycles. CDK 9, along with CDK 7 and CDK 8 are involved in controlling RNA-polymerase-II- (pol II-) mediated transcription.

Cyclin-dependent protein kinase pair complex forms a part of a multiprotein complex called TAK/P-TEFb, which facilitates the phosphorylation of C- terminal domain of the larger subunit of RNA polymerase II. The protein later forms a complex with its regulatory subunit cyclin Kor cyclin T. CDK inhibitors have the potentials to inhibit the functions of CDK, which is widely being employed for preventing the over-proliferation of cancer cells.

CDK 9 inhibitors have emerged as a potential protein for the development of effective cancer therapy owing to their anti-tumor activity. Many pharmaceutical companies are continuously focusing on studying and developing novel treatment options using CDK9 inhibitors for cancer, which is one of the most prevalent diseases. For instance; AZD4573 is being studied by AstraZeneca for a relapsed or refractory form of hematological malignancies including acute myeloid leukemia, Non-Hodgkin lymphoma, and others which is currently in phase-2 clinical trials.

At present, around 80% of the pipeline candidates for Cyclin-Dependent Kinase 9 (CDK9) Inhibitors are in the phase 1 stage. All the studies are sponsored by pharmaceutical industries.

Report Description

The report on ‘Cyclin-Dependent Kinase 9 (CDK9) Inhibitor – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Cyclin-Dependent Kinase 9 (CDK9) Inhibitor. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Cyclin-Dependent Kinase 9 (CDK9) Inhibitor.

The report on ‘Cyclin-Dependent Kinase 9 (CDK9) Inhibitor – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Cyclin-Dependent Kinase 9 (CDK9) Inhibitor
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Cyclin-Dependent Kinase 9 (CDK9) Inhibitor
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary